Analysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $24.38
by Doug Wharley · The Cerbat GemShares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $24.3750.
A number of equities research analysts recently issued reports on the company. Barclays upped their target price on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a report on Friday, March 27th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $13.00 price target (down from $18.00) on shares of Xencor in a report on Tuesday, March 24th. Finally, Wall Street Zen downgraded Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th.
Read Our Latest Analysis on Xencor
Insider Transactions at Xencor
In other news, VP John R. Desjarlais sold 4,118 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $46,327.50. Following the transaction, the vice president owned 266,333 shares of the company’s stock, valued at approximately $2,996,246.25. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bassil I. Dahiyat sold 14,870 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $167,287.50. Following the transaction, the chief executive officer directly owned 552,922 shares in the company, valued at $6,220,372.50. The trade was a 2.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 44,020 shares of company stock valued at $499,817. Insiders own 4.76% of the company’s stock.
Institutional Investors Weigh In On Xencor
Several large investors have recently made changes to their positions in XNCR. BVF Inc. IL increased its stake in shares of Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after purchasing an additional 4,393,579 shares during the period. Legal & General Group Plc increased its stake in shares of Xencor by 603.7% during the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after acquiring an additional 1,092,095 shares during the period. State Street Corp increased its stake in shares of Xencor by 22.7% during the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after acquiring an additional 833,423 shares during the period. Jefferies Financial Group Inc. boosted its holdings in Xencor by 620.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock worth $11,030,000 after buying an additional 620,440 shares in the last quarter. Finally, RTW Investments LP boosted its holdings in Xencor by 8.9% during the fourth quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after buying an additional 556,407 shares in the last quarter.
Xencor Price Performance
XNCR stock opened at $12.42 on Friday. Xencor has a 1 year low of $6.92 and a 1 year high of $18.69. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. The stock’s 50 day moving average price is $11.99 and its 200 day moving average price is $13.55. The firm has a market cap of $910.87 million, a P/E ratio of -10.02 and a beta of 0.99.
Xencor (NASDAQ:XNCR – Get Free Report) last posted its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The firm had revenue of $28.24 million for the quarter, compared to analyst estimates of $29.97 million. During the same quarter in the prior year, the company earned ($0.62) EPS. Xencor’s revenue was down 46.6% on a year-over-year basis. On average, sell-side analysts expect that Xencor will post -3.68 earnings per share for the current fiscal year.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.